President Yoweri Kaguta Museveni has applauded Dr. Matthias Magoola, the founder and Managing Director of Dei Biopharma Ltd, for his extraordinary achievements in medical innovation, following the filing of over 100 patents with the United States Patent and Trademark Office (USPTO) for treatments targeting a wide range of diseases.
Museveni revealed he had met with Dr. Magoola to receive updates on the company’s groundbreaking projects and expressed admiration for the scale and ambition of Dei Biopharma’s work, which includes research and development of treatments for cancer, HIV, Alzheimer’s, malaria, tuberculosis, and diabetes.
“I am happy to learn that he has filed over 100 patents with the United States Patent Office for treating different diseases… some of which have been granted,” Museveni said.
Museveni affirmed the government’s commitment to facilitating the necessary regulatory processes to ensure Dei Biopharma’s drugs can be licensed and produced locally for both domestic and international markets.
“The government will support his company with the necessary accreditation requirements in order to obtain licenses for drugs to be produced locally for use in global markets,” he assured.
The President’s endorsement follows growing national and international attention on Dei Biopharma, particularly after Dr. Magoola secured a U.S. patent for an innovative cancer treatment drug.
Minister for the Presidency, Hon. Milly Babalanda also praised Dr. Magoola for what she described as a “big achievement” for Uganda and the wider scientific community.
“I congratulate Dr. Matthias Magoola upon securing a US patent for his cancer treatment drug,” Babalanda stated.
She added, “This is a big achievement and a step in the right direction for scientific innovation contributing to a better world.”
The Minister also expressed gratitude to President Museveni for his unwavering support of Dr. Magoola’s vision, including the establishment of a state-of-the-art pharmaceuticals factory in Matugga.
“I thank the President for believing in Dr. Magoola’s vision and supporting the setting up of the modern pharmaceuticals factory at Matugga for drugs and vaccines against various ailments including HIV/AIDS and sickle cell,” she noted.
Hon. Babalanda further called on Ugandans to take pride in locally driven innovation, urging, “As Ugandans, we should be proud and support our own,”
Dei BioPharma Ltd is a Uganda-funded research-based drugs and vaccines manufacturing firm located in Matugga, Wakiso District. It is the largest pharmaceutical manufacturing and also the first biotechnology products company that will introduce most advanced technologies such as mRNA, gene therapy, novel vaccines, and recombinant drugs, besides other essential medicines in Uganda that are compliant with stringent regulatory country good manufacturing practices.
